| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 35 | 2026 | 1195 | 3.280 |
Why?
|
| Lung Neoplasms | 46 | 2026 | 2679 | 3.220 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2026 | 984 | 2.880 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 11 | 2019 | 59 | 2.080 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2026 | 889 | 1.830 |
Why?
|
| Head and Neck Neoplasms | 11 | 2022 | 569 | 1.640 |
Why?
|
| Mitogen-Activated Protein Kinases | 18 | 2020 | 288 | 1.610 |
Why?
|
| Carcinoma, Squamous Cell | 11 | 2021 | 648 | 1.410 |
Why?
|
| ErbB Receptors | 13 | 2023 | 638 | 1.370 |
Why?
|
| Signal Transduction | 39 | 2026 | 5272 | 1.350 |
Why?
|
| Receptors, Fibroblast Growth Factor | 5 | 2013 | 71 | 1.350 |
Why?
|
| Cell Line, Tumor | 37 | 2026 | 3565 | 1.270 |
Why?
|
| Protein Kinases | 16 | 2019 | 312 | 1.210 |
Why?
|
| Carcinoma, Small Cell | 6 | 2021 | 173 | 1.190 |
Why?
|
| Antineoplastic Agents | 18 | 2021 | 2231 | 1.140 |
Why?
|
| RNA Interference | 7 | 2019 | 477 | 1.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 19 | 2018 | 153 | 1.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 19 | 1999 | 165 | 1.010 |
Why?
|
| Mesothelioma | 2 | 2019 | 52 | 0.970 |
Why?
|
| Cell Proliferation | 24 | 2026 | 2529 | 0.960 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2026 | 41 | 0.930 |
Why?
|
| Genomics | 3 | 2019 | 839 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2021 | 1457 | 0.770 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 8 | 2026 | 256 | 0.720 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2018 | 231 | 0.710 |
Why?
|
| Adenocarcinoma | 4 | 2026 | 928 | 0.690 |
Why?
|
| Furans | 1 | 2021 | 26 | 0.670 |
Why?
|
| Gene Amplification | 6 | 2015 | 118 | 0.670 |
Why?
|
| B7-H1 Antigen | 5 | 2026 | 246 | 0.660 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 340 | 0.660 |
Why?
|
| Ketones | 1 | 2021 | 51 | 0.650 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2018 | 627 | 0.630 |
Why?
|
| Animals | 82 | 2026 | 38410 | 0.630 |
Why?
|
| Cetuximab | 3 | 2021 | 111 | 0.620 |
Why?
|
| Autocrine Communication | 3 | 2014 | 38 | 0.610 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 200 | 0.600 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2026 | 76 | 0.580 |
Why?
|
| Gene Dosage | 4 | 2018 | 145 | 0.580 |
Why?
|
| GTP-Binding Proteins | 13 | 1997 | 153 | 0.580 |
Why?
|
| Precision Medicine | 2 | 2021 | 464 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2026 | 2001 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-jun | 6 | 2024 | 54 | 0.540 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 98 | 0.510 |
Why?
|
| Quinazolines | 4 | 2016 | 266 | 0.500 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 536 | 0.500 |
Why?
|
| Tumor Cells, Cultured | 19 | 2020 | 891 | 0.500 |
Why?
|
| Mutation | 24 | 2026 | 4130 | 0.490 |
Why?
|
| Isoenzymes | 9 | 2006 | 296 | 0.480 |
Why?
|
| Neoplasms | 5 | 2019 | 2946 | 0.480 |
Why?
|
| Drug Resistance | 1 | 2017 | 145 | 0.470 |
Why?
|
| Mice | 34 | 2026 | 18491 | 0.470 |
Why?
|
| RNA, Messenger | 16 | 2018 | 2812 | 0.450 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2016 | 15 | 0.450 |
Why?
|
| Pyrazoles | 5 | 2026 | 518 | 0.450 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2015 | 55 | 0.440 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 33 | 0.430 |
Why?
|
| Wnt Proteins | 5 | 2013 | 133 | 0.430 |
Why?
|
| Enzyme Activation | 29 | 2013 | 762 | 0.430 |
Why?
|
| Cell Differentiation | 11 | 2005 | 2054 | 0.430 |
Why?
|
| Cytoskeletal Proteins | 3 | 2004 | 158 | 0.420 |
Why?
|
| Biomarkers, Tumor | 7 | 2026 | 1339 | 0.410 |
Why?
|
| Pleural Neoplasms | 1 | 2014 | 31 | 0.410 |
Why?
|
| Humans | 84 | 2026 | 147293 | 0.410 |
Why?
|
| Pluripotent Stem Cells | 2 | 2005 | 81 | 0.410 |
Why?
|
| Protein Isoforms | 3 | 2018 | 398 | 0.400 |
Why?
|
| Cyclic AMP | 13 | 1996 | 208 | 0.400 |
Why?
|
| Nerve Growth Factor | 2 | 2004 | 37 | 0.390 |
Why?
|
| Neurofilament Proteins | 2 | 2005 | 83 | 0.390 |
Why?
|
| Immunoblotting | 8 | 2017 | 296 | 0.380 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2013 | 3 | 0.380 |
Why?
|
| Immunity, Innate | 1 | 2019 | 840 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 456 | 0.380 |
Why?
|
| Pyridazines | 4 | 2018 | 57 | 0.370 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2020 | 174 | 0.370 |
Why?
|
| Imidazoles | 5 | 2018 | 247 | 0.350 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2014 | 980 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2024 | 939 | 0.350 |
Why?
|
| Cell Line | 23 | 2018 | 2832 | 0.340 |
Why?
|
| Transfection | 21 | 2016 | 930 | 0.330 |
Why?
|
| Phospholipases A | 6 | 2001 | 97 | 0.330 |
Why?
|
| Pyrimidines | 4 | 2023 | 532 | 0.330 |
Why?
|
| Kidney Tubules, Collecting | 5 | 2000 | 27 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 4 | 2005 | 14 | 0.330 |
Why?
|
| Gene Expression Regulation | 6 | 2004 | 2625 | 0.330 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 28 | 0.330 |
Why?
|
| Loss of Function Mutation | 2 | 2021 | 46 | 0.320 |
Why?
|
| Receptor, EphB4 | 2 | 2022 | 33 | 0.310 |
Why?
|
| Ephrin-B2 | 2 | 2022 | 45 | 0.310 |
Why?
|
| RNA, Small Interfering | 5 | 2017 | 643 | 0.310 |
Why?
|
| Cell Survival | 7 | 2021 | 1111 | 0.310 |
Why?
|
| Prostaglandins A | 5 | 1988 | 9 | 0.290 |
Why?
|
| Fibroblast Growth Factor 2 | 4 | 2016 | 94 | 0.290 |
Why?
|
| Blotting, Western | 8 | 2014 | 1186 | 0.280 |
Why?
|
| Fibroblast Growth Factors | 2 | 2015 | 188 | 0.280 |
Why?
|
| GTP Phosphohydrolases | 4 | 1996 | 95 | 0.280 |
Why?
|
| Neurons | 6 | 2005 | 1672 | 0.280 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2020 | 364 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 8 | 2007 | 1253 | 0.270 |
Why?
|
| Oncogenes | 4 | 2023 | 118 | 0.270 |
Why?
|
| Cell Division | 7 | 2004 | 758 | 0.270 |
Why?
|
| Morpholines | 3 | 2018 | 130 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2000 | 126 | 0.260 |
Why?
|
| Pyridines | 4 | 2026 | 610 | 0.260 |
Why?
|
| Trans-Activators | 4 | 2020 | 398 | 0.250 |
Why?
|
| PC12 Cells | 9 | 2004 | 42 | 0.250 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2013 | 432 | 0.250 |
Why?
|
| Genes, ras | 5 | 2001 | 96 | 0.240 |
Why?
|
| Genes, Essential | 2 | 2017 | 19 | 0.240 |
Why?
|
| src-Family Kinases | 2 | 2024 | 93 | 0.230 |
Why?
|
| Benzamides | 2 | 2018 | 227 | 0.230 |
Why?
|
| Polyamines | 1 | 2026 | 42 | 0.230 |
Why?
|
| Gene Library | 2 | 2017 | 122 | 0.230 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2019 | 415 | 0.230 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 748 | 0.220 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2004 | 751 | 0.220 |
Why?
|
| Epidermal Growth Factor | 6 | 2013 | 162 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 444 | 0.220 |
Why?
|
| Kidney Medulla | 4 | 1998 | 31 | 0.220 |
Why?
|
| Protein Binding | 4 | 2018 | 2249 | 0.220 |
Why?
|
| Rats | 23 | 2008 | 5613 | 0.220 |
Why?
|
| Frizzled Receptors | 4 | 2013 | 25 | 0.220 |
Why?
|
| Type C Phospholipases | 6 | 2000 | 69 | 0.210 |
Why?
|
| Mice, Nude | 6 | 2019 | 680 | 0.210 |
Why?
|
| Dasatinib | 1 | 2024 | 58 | 0.210 |
Why?
|
| Protein Kinase C | 6 | 2000 | 251 | 0.210 |
Why?
|
| Piperazines | 2 | 2018 | 375 | 0.210 |
Why?
|
| Protein Kinase C-delta | 2 | 2017 | 45 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 4 | 2007 | 308 | 0.200 |
Why?
|
| Aniline Compounds | 2 | 2023 | 120 | 0.200 |
Why?
|
| Phosphorylation | 14 | 2018 | 1721 | 0.200 |
Why?
|
| Cadherins | 4 | 2017 | 204 | 0.190 |
Why?
|
| Interferons | 2 | 2021 | 186 | 0.190 |
Why?
|
| Azacitidine | 1 | 2004 | 168 | 0.190 |
Why?
|
| Platinum Compounds | 1 | 2002 | 10 | 0.190 |
Why?
|
| Apoptosis | 9 | 2018 | 2454 | 0.180 |
Why?
|
| Acrylamides | 1 | 2023 | 74 | 0.180 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 1794 | 0.180 |
Why?
|
| Cyclooxygenase 2 | 5 | 2008 | 167 | 0.180 |
Why?
|
| HEK293 Cells | 3 | 2019 | 745 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2017 | 337 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2017 | 672 | 0.180 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1281 | 0.170 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 4 | 2012 | 14 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2023 | 171 | 0.170 |
Why?
|
| Gene Expression | 5 | 2015 | 1481 | 0.170 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2005 | 915 | 0.170 |
Why?
|
| Receptors, Neuropeptide | 1 | 2001 | 6 | 0.170 |
Why?
|
| Nerve Growth Factors | 4 | 1997 | 79 | 0.170 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2021 | 91 | 0.170 |
Why?
|
| A549 Cells | 1 | 2021 | 75 | 0.170 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 103 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 1266 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 6 | 2026 | 6041 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 4 | 2010 | 17 | 0.160 |
Why?
|
| Carrier Proteins | 2 | 2000 | 731 | 0.160 |
Why?
|
| Paracrine Communication | 1 | 2001 | 67 | 0.160 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 4 | 2002 | 76 | 0.160 |
Why?
|
| PPAR gamma | 4 | 2013 | 182 | 0.160 |
Why?
|
| Pheochromocytoma | 3 | 1990 | 67 | 0.160 |
Why?
|
| Tumor Burden | 3 | 2018 | 327 | 0.150 |
Why?
|
| Radioimmunotherapy | 1 | 2019 | 25 | 0.150 |
Why?
|
| MAP Kinase Kinase 7 | 2 | 2018 | 8 | 0.150 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2012 | 85 | 0.150 |
Why?
|
| Lymphocyte Depletion | 1 | 2019 | 133 | 0.150 |
Why?
|
| Point Mutation | 2 | 1997 | 245 | 0.150 |
Why?
|
| Base Sequence | 8 | 2005 | 2175 | 0.150 |
Why?
|
| Proteins | 2 | 2005 | 1024 | 0.150 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2019 | 56 | 0.150 |
Why?
|
| Luciferases | 5 | 2010 | 155 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 268 | 0.140 |
Why?
|
| Papillomaviridae | 1 | 2019 | 116 | 0.140 |
Why?
|
| beta Catenin | 4 | 2008 | 254 | 0.140 |
Why?
|
| Drug Synergism | 3 | 2015 | 355 | 0.140 |
Why?
|
| Indoles | 1 | 2023 | 510 | 0.140 |
Why?
|
| c-Mer Tyrosine Kinase | 2 | 2016 | 39 | 0.140 |
Why?
|
| Receptor, EphB3 | 1 | 2018 | 4 | 0.140 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 166 | 0.140 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 28 | 0.140 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 144 | 0.140 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2018 | 59 | 0.140 |
Why?
|
| Monocytes | 1 | 2001 | 539 | 0.140 |
Why?
|
| Cell Movement | 3 | 2018 | 966 | 0.130 |
Why?
|
| gamma Catenin | 3 | 2018 | 13 | 0.130 |
Why?
|
| Kinetics | 11 | 2002 | 1569 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 215 | 0.130 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 56 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 108 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2000 | 430 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 374 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2018 | 129 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2008 | 669 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2017 | 212 | 0.130 |
Why?
|
| Ultraviolet Therapy | 1 | 1997 | 17 | 0.130 |
Why?
|
| Hypertonic Solutions | 1 | 1997 | 7 | 0.130 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 122 | 0.130 |
Why?
|
| Growth Substances | 2 | 2000 | 138 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 156 | 0.130 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2017 | 4 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 200 | 0.130 |
Why?
|
| Securin | 1 | 2016 | 2 | 0.120 |
Why?
|
| Glutathione | 4 | 1988 | 370 | 0.120 |
Why?
|
| Adenylyl Cyclases | 4 | 1991 | 60 | 0.120 |
Why?
|
| Down-Regulation | 5 | 2017 | 618 | 0.120 |
Why?
|
| Erythrocytes | 4 | 1988 | 749 | 0.120 |
Why?
|
| Alternative Splicing | 2 | 2018 | 248 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2010 | 232 | 0.120 |
Why?
|
| Macrophages | 2 | 2019 | 1529 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 113 | 0.120 |
Why?
|
| Clone Cells | 3 | 2014 | 263 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 345 | 0.110 |
Why?
|
| ras Proteins | 4 | 2012 | 153 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 708 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2013 | 19 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 745 | 0.110 |
Why?
|
| Benzodioxoles | 1 | 2016 | 162 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 196 | 0.110 |
Why?
|
| Guanosine Triphosphate | 4 | 1991 | 89 | 0.100 |
Why?
|
| Amino Acid Sequence | 12 | 2018 | 2134 | 0.100 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4604 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 780 | 0.100 |
Why?
|
| Hormones | 1 | 1994 | 136 | 0.100 |
Why?
|
| Growth Inhibitors | 1 | 2013 | 39 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 1995 | 373 | 0.100 |
Why?
|
| Computational Biology | 2 | 2015 | 677 | 0.100 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2014 | 67 | 0.100 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2015 | 125 | 0.100 |
Why?
|
| Desmoplakins | 2 | 2004 | 25 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 539 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1492 | 0.100 |
Why?
|
| Leukemia | 1 | 2015 | 247 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 220 | 0.090 |
Why?
|
| Transcription Factors | 4 | 2004 | 1747 | 0.090 |
Why?
|
| Genes, src | 1 | 1992 | 5 | 0.090 |
Why?
|
| Chimera | 4 | 1991 | 62 | 0.090 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 1992 | 4 | 0.090 |
Why?
|
| RNA Splicing | 1 | 2014 | 285 | 0.090 |
Why?
|
| Molecular Sequence Data | 12 | 2008 | 2886 | 0.090 |
Why?
|
| Female | 21 | 2026 | 80076 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2004 | 318 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 300 | 0.090 |
Why?
|
| Tyrosine | 6 | 1997 | 218 | 0.090 |
Why?
|
| DNA Replication | 2 | 2010 | 250 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 694 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2015 | 6099 | 0.090 |
Why?
|
| Phospholipases A2 | 6 | 2001 | 79 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 2 | 2013 | 16 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 212 | 0.090 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1991 | 20 | 0.080 |
Why?
|
| Gene Transfer Techniques | 3 | 2006 | 189 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 126 | 0.080 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2010 | 15 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2018 | 450 | 0.080 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 1990 | 15 | 0.080 |
Why?
|
| Thionucleotides | 2 | 1990 | 35 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2458 | 0.080 |
Why?
|
| Algorithms | 2 | 2015 | 1868 | 0.080 |
Why?
|
| Up-Regulation | 4 | 2016 | 848 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 5476 | 0.080 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2010 | 15 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 3 | 2017 | 334 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 599 | 0.080 |
Why?
|
| Cells, Cultured | 10 | 1998 | 4169 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 318 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 1166 | 0.080 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 35 | 0.080 |
Why?
|
| Coculture Techniques | 1 | 2010 | 247 | 0.080 |
Why?
|
| Iloprost | 1 | 2010 | 45 | 0.080 |
Why?
|
| Male | 22 | 2026 | 73950 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3784 | 0.070 |
Why?
|
| Prognosis | 4 | 2026 | 4383 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2010 | 68 | 0.070 |
Why?
|
| Retroviridae | 2 | 2002 | 100 | 0.070 |
Why?
|
| DNA Primers | 2 | 2001 | 505 | 0.070 |
Why?
|
| Transcriptional Activation | 3 | 2014 | 372 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2002 | 387 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 1990 | 99 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 330 | 0.070 |
Why?
|
| Intercellular Junctions | 1 | 2008 | 35 | 0.070 |
Why?
|
| Middle Aged | 11 | 2026 | 36821 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2015 | 787 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2010 | 1039 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 224 | 0.070 |
Why?
|
| Substance P | 2 | 2001 | 38 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 133 | 0.070 |
Why?
|
| Cisplatin | 2 | 2017 | 347 | 0.070 |
Why?
|
| Erythrocyte Membrane | 2 | 1985 | 55 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2010 | 358 | 0.070 |
Why?
|
| 3T3 Cells | 4 | 2002 | 157 | 0.060 |
Why?
|
| Genes, Reporter | 2 | 2005 | 278 | 0.060 |
Why?
|
| Dinoprostone | 4 | 2007 | 180 | 0.060 |
Why?
|
| Aged | 8 | 2026 | 26514 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 1997 | 149 | 0.060 |
Why?
|
| Veterans | 1 | 2019 | 1675 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2010 | 445 | 0.060 |
Why?
|
| Inflammation | 1 | 2018 | 2920 | 0.060 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2006 | 20 | 0.060 |
Why?
|
| Enzyme Inhibitors | 5 | 2007 | 822 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 1730 | 0.060 |
Why?
|
| Enzyme Induction | 3 | 2008 | 88 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2005 | 264 | 0.060 |
Why?
|
| Survival Rate | 2 | 2026 | 2110 | 0.060 |
Why?
|
| Sodium Channels | 2 | 1997 | 63 | 0.060 |
Why?
|
| Columbidae | 4 | 1988 | 31 | 0.060 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 124 | 0.060 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2005 | 21 | 0.060 |
Why?
|
| MAP Kinase Kinase Kinase 4 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2004 | 196 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2007 | 676 | 0.060 |
Why?
|
| Wnt4 Protein | 1 | 2005 | 20 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 855 | 0.060 |
Why?
|
| Amino Acids | 2 | 1990 | 519 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 522 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2007 | 440 | 0.060 |
Why?
|
| Bone Development | 1 | 2005 | 52 | 0.060 |
Why?
|
| Models, Biological | 4 | 2016 | 1772 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 876 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2008 | 82 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2026 | 156 | 0.050 |
Why?
|
| Cyclic AMP Receptor Protein | 1 | 1985 | 2 | 0.050 |
Why?
|
| Actins | 2 | 1997 | 428 | 0.050 |
Why?
|
| Synapsins | 1 | 2004 | 13 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2024 | 25 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 234 | 0.050 |
Why?
|
| Neural Tube Defects | 1 | 2005 | 67 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 83 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2007 | 381 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 975 | 0.050 |
Why?
|
| fas Receptor | 1 | 2004 | 91 | 0.050 |
Why?
|
| Neoplasms, Experimental | 3 | 2007 | 167 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 376 | 0.050 |
Why?
|
| DNA Modification Methylases | 1 | 2004 | 19 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2004 | 92 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 512 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2004 | 95 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 323 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 1093 | 0.050 |
Why?
|
| Disease Progression | 3 | 2018 | 2890 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 459 | 0.050 |
Why?
|
| Cytosol | 3 | 2001 | 213 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 151 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 1046 | 0.050 |
Why?
|
| DNA | 6 | 2005 | 1444 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 338 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2000 | 172 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 287 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2008 | 1141 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2002 | 154 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 10 | 1 | 2001 | 4 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 90 | 0.040 |
Why?
|
| Immune Sera | 1 | 2001 | 77 | 0.040 |
Why?
|
| Thrombin | 2 | 1994 | 174 | 0.040 |
Why?
|
| Chromaffin Cells | 1 | 2000 | 4 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 445 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 212 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2016 | 269 | 0.040 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 2000 | 11 | 0.040 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2000 | 11 | 0.040 |
Why?
|
| I-kappa B Proteins | 1 | 2001 | 75 | 0.040 |
Why?
|
| Lung | 2 | 2008 | 4141 | 0.040 |
Why?
|
| Flavonoids | 2 | 2001 | 85 | 0.040 |
Why?
|
| Prolactin | 1 | 2000 | 88 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2021 | 234 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2001 | 191 | 0.040 |
Why?
|
| Cytoplasm | 2 | 2018 | 255 | 0.040 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2000 | 17 | 0.040 |
Why?
|
| Peptide Fragments | 3 | 1993 | 698 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2000 | 55 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2000 | 75 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2000 | 50 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 86 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1514 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1999 | 34 | 0.040 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2019 | 40 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 84 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2000 | 148 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 347 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2019 | 1302 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 146 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 1997 | 1171 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 878 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2000 | 1371 | 0.040 |
Why?
|
| Osmotic Pressure | 1 | 1999 | 41 | 0.040 |
Why?
|
| Neurites | 2 | 1997 | 51 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 241 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 77 | 0.040 |
Why?
|
| Arginine Vasopressin | 2 | 1995 | 44 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 1998 | 37 | 0.040 |
Why?
|
| Desmoglein 3 | 1 | 2018 | 14 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 177 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 210 | 0.030 |
Why?
|
| Adult | 5 | 2026 | 41405 | 0.030 |
Why?
|
| COS Cells | 1 | 2018 | 177 | 0.030 |
Why?
|
| Metaplasia | 1 | 2018 | 57 | 0.030 |
Why?
|
| Cricetinae | 4 | 1994 | 305 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 2018 | 38 | 0.030 |
Why?
|
| Transgenes | 2 | 2010 | 190 | 0.030 |
Why?
|
| Phospholipase C beta | 1 | 1998 | 30 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 2030 | 0.030 |
Why?
|
| Mitogens | 1 | 1998 | 55 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2001 | 324 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 1998 | 140 | 0.030 |
Why?
|
| Peptides | 3 | 1994 | 1003 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 97 | 0.030 |
Why?
|
| Phenotype | 4 | 2005 | 3216 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 37 | 0.030 |
Why?
|
| Binding Sites | 2 | 2018 | 1319 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 863 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 2017 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2018 | 100 | 0.030 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1997 | 12 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2018 | 210 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2019 | 370 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2017 | 43 | 0.030 |
Why?
|
| Vinblastine | 1 | 2017 | 75 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 72 | 0.030 |
Why?
|
| Mannitol | 1 | 1997 | 40 | 0.030 |
Why?
|
| Liver | 2 | 1996 | 1916 | 0.030 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1997 | 43 | 0.030 |
Why?
|
| Plasmids | 4 | 1990 | 373 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 1998 | 138 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2020 | 786 | 0.030 |
Why?
|
| Bronchi | 1 | 2018 | 263 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1996 | 15 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2018 | 274 | 0.030 |
Why?
|
| Pertussis Toxin | 1 | 1996 | 24 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-raf | 4 | 1997 | 46 | 0.030 |
Why?
|
| Arachidonic Acid | 2 | 1994 | 102 | 0.030 |
Why?
|
| Mice, Mutant Strains | 2 | 2007 | 303 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 1997 | 216 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 311 | 0.030 |
Why?
|
| Sulfonamides | 2 | 2016 | 596 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 385 | 0.030 |
Why?
|
| Molecular Weight | 2 | 1994 | 313 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2016 | 76 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 695 | 0.030 |
Why?
|
| Receptors, Growth Factor | 1 | 1995 | 53 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 203 | 0.030 |
Why?
|
| Kidney Cortex | 1 | 1995 | 27 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 442 | 0.030 |
Why?
|
| Bombesin | 1 | 1995 | 10 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 589 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 120 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1386 | 0.030 |
Why?
|
| Muscarine | 1 | 1994 | 3 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 932 | 0.030 |
Why?
|
| Carbachol | 1 | 1994 | 17 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 318 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 1993 | 335 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1994 | 55 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 240 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 1994 | 137 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 633 | 0.030 |
Why?
|
| Vasopressins | 1 | 1994 | 61 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 746 | 0.030 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2013 | 2 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 776 | 0.030 |
Why?
|
| Adenosine Triphosphate | 2 | 1994 | 500 | 0.020 |
Why?
|
| Cell Polarity | 1 | 1994 | 137 | 0.020 |
Why?
|
| Purines | 1 | 1994 | 188 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 178 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 249 | 0.020 |
Why?
|
| Thermolysin | 1 | 1993 | 4 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2011 | 3153 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 8430 | 0.020 |
Why?
|
| Glomerular Mesangium | 1 | 1993 | 21 | 0.020 |
Why?
|
| Ligands | 1 | 2015 | 675 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 194 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 313 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 1993 | 73 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 1993 | 62 | 0.020 |
Why?
|
| Exons | 1 | 2014 | 365 | 0.020 |
Why?
|
| Endoscopy | 1 | 2015 | 322 | 0.020 |
Why?
|
| Nitriles | 1 | 2014 | 211 | 0.020 |
Why?
|
| Trypsin | 1 | 1993 | 75 | 0.020 |
Why?
|
| Cricetulus | 2 | 1990 | 118 | 0.020 |
Why?
|
| Genes, jun | 1 | 1992 | 9 | 0.020 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1992 | 10 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 192 | 0.020 |
Why?
|
| Guanosine Diphosphate | 2 | 1991 | 20 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 49 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1344 | 0.020 |
Why?
|
| In Vitro Techniques | 3 | 1994 | 1049 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1992 | 35 | 0.020 |
Why?
|
| Microbial Collagenase | 1 | 1992 | 8 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 149 | 0.020 |
Why?
|
| Escherichia coli | 2 | 1993 | 836 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 443 | 0.020 |
Why?
|
| Adenovirus Early Proteins | 1 | 1991 | 2 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 4 | 1998 | 2542 | 0.020 |
Why?
|
| Calcium | 2 | 1995 | 1197 | 0.020 |
Why?
|
| Urethane | 1 | 2011 | 43 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1990 | 26 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 190 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1990 | 67 | 0.020 |
Why?
|
| Phospholipases | 1 | 1990 | 14 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1994 | 679 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 514 | 0.020 |
Why?
|
| Receptors, Purinergic | 1 | 1990 | 20 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2010 | 14 | 0.020 |
Why?
|
| Replication Protein A | 1 | 2010 | 14 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1990 | 24 | 0.020 |
Why?
|
| G1 Phase | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Caffeine | 1 | 2010 | 76 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2010 | 91 | 0.020 |
Why?
|
| Digitonin | 1 | 1989 | 5 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 1989 | 13 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2010 | 130 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 552 | 0.020 |
Why?
|
| Osmolar Concentration | 2 | 2000 | 168 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1989 | 131 | 0.020 |
Why?
|
| Valine | 1 | 1989 | 83 | 0.020 |
Why?
|
| Guanine Nucleotides | 1 | 1988 | 12 | 0.020 |
Why?
|
| Cell Shape | 1 | 2008 | 56 | 0.020 |
Why?
|
| Receptors, Adrenergic | 1 | 1988 | 20 | 0.020 |
Why?
|
| Receptors, Muscarinic | 1 | 1988 | 20 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 1488 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2010 | 392 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 383 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2008 | 108 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 3448 | 0.020 |
Why?
|
| Prostaglandins A, Synthetic | 1 | 1988 | 1 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 176 | 0.020 |
Why?
|
| Glycine | 1 | 1989 | 186 | 0.020 |
Why?
|
| Sulindac | 1 | 2007 | 16 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 45 | 0.020 |
Why?
|
| Ovary | 1 | 1990 | 236 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2000 | 136 | 0.020 |
Why?
|
| Prostaglandins | 1 | 1988 | 94 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 154 | 0.020 |
Why?
|
| Culture Media | 1 | 2007 | 161 | 0.020 |
Why?
|
| DNA Damage | 1 | 2010 | 440 | 0.020 |
Why?
|
| Macromolecular Substances | 3 | 1994 | 216 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1606 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 165 | 0.010 |
Why?
|
| Transcription, Genetic | 2 | 1992 | 1456 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2000 | 383 | 0.010 |
Why?
|
| Phospholipase C gamma | 2 | 1997 | 28 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 1997 | 31 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 375 | 0.010 |
Why?
|
| Restriction Mapping | 3 | 1990 | 81 | 0.010 |
Why?
|
| Hepatocyte Growth Factor | 2 | 1996 | 33 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1985 | 24 | 0.010 |
Why?
|
| Tritium | 1 | 1985 | 67 | 0.010 |
Why?
|
| Suspensions | 1 | 1985 | 28 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2005 | 81 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 2006 | 84 | 0.010 |
Why?
|
| Rhombencephalon | 1 | 2005 | 31 | 0.010 |
Why?
|
| Phosphotyrosine | 2 | 1995 | 38 | 0.010 |
Why?
|
| Thioinosine | 1 | 1985 | 1 | 0.010 |
Why?
|
| Cytochalasin B | 1 | 1985 | 8 | 0.010 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1985 | 6 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1985 | 16 | 0.010 |
Why?
|
| Ouabain | 1 | 1985 | 18 | 0.010 |
Why?
|
| Rubidium | 1 | 1985 | 11 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 7173 | 0.010 |
Why?
|
| Temperature | 2 | 1985 | 638 | 0.010 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2004 | 20 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 61 | 0.010 |
Why?
|
| Body Patterning | 1 | 2005 | 138 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2004 | 115 | 0.010 |
Why?
|
| Potassium Cyanide | 1 | 1985 | 24 | 0.010 |
Why?
|
| Histones | 1 | 2010 | 672 | 0.010 |
Why?
|
| Birds | 1 | 1985 | 87 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2004 | 278 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 1995 | 377 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1985 | 593 | 0.010 |
Why?
|
| CHO Cells | 2 | 1994 | 169 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 2197 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 246 | 0.010 |
Why?
|
| Salmonella Phages | 1 | 1982 | 3 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 499 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1985 | 1077 | 0.010 |
Why?
|
| United States | 1 | 2019 | 16313 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 11017 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 1982 | 95 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2001 | 50 | 0.010 |
Why?
|
| Receptors, Prolactin | 1 | 2000 | 6 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 23 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2000 | 24 | 0.010 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2000 | 2 | 0.010 |
Why?
|
| Nitrobenzenes | 1 | 2000 | 15 | 0.010 |
Why?
|
| Estrenes | 1 | 2000 | 13 | 0.010 |
Why?
|
| Granulocytes | 1 | 2000 | 83 | 0.010 |
Why?
|
| Pyrrolidinones | 1 | 2000 | 29 | 0.010 |
Why?
|
| Genes, fos | 1 | 2000 | 36 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2000 | 92 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1982 | 536 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 1990 | 24 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 2000 | 149 | 0.010 |
Why?
|
| Chemoprevention | 1 | 1999 | 92 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 567 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 14437 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 381 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1992 | 480 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 1000 | 0.010 |
Why?
|
| Sheep | 1 | 2000 | 879 | 0.010 |
Why?
|
| Cell Membrane | 2 | 1991 | 711 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1997 | 10 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1997 | 16 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 1997 | 39 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 1997 | 27 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1997 | 23 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1997 | 51 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 2086 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1999 | 600 | 0.010 |
Why?
|
| GTPase-Activating Proteins | 1 | 1997 | 81 | 0.010 |
Why?
|
| Biological Transport | 1 | 1998 | 425 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 22825 | 0.010 |
Why?
|
| Child | 1 | 2016 | 22979 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 1997 | 289 | 0.010 |
Why?
|
| Stem Cells | 1 | 2000 | 630 | 0.010 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1995 | 14 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1997 | 167 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1995 | 102 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 1994 | 11 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1994 | 16 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1995 | 125 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1985 | 2359 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1995 | 414 | 0.010 |
Why?
|
| Cholera Toxin | 1 | 1994 | 29 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1998 | 567 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1994 | 141 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1992 | 44 | 0.010 |
Why?
|
| Oncogene Proteins v-raf | 1 | 1992 | 2 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1992 | 50 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 7274 | 0.010 |
Why?
|
| Moths | 1 | 1992 | 45 | 0.010 |
Why?
|
| Phospholipids | 1 | 1994 | 214 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 1990 | 32 | 0.010 |
Why?
|
| Lithium Chloride | 1 | 1990 | 14 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 1990 | 21 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 1990 | 41 | 0.000 |
Why?
|
| Myristic Acids | 1 | 1990 | 8 | 0.000 |
Why?
|
| Models, Structural | 1 | 1990 | 41 | 0.000 |
Why?
|
| Lithium | 1 | 1990 | 40 | 0.000 |
Why?
|
| Myristic Acid | 1 | 1990 | 10 | 0.000 |
Why?
|
| Arachidonic Acids | 1 | 1990 | 42 | 0.000 |
Why?
|
| Isoproterenol | 1 | 1990 | 96 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 539 | 0.000 |
Why?
|
| Chlorides | 1 | 1990 | 138 | 0.000 |
Why?
|
| Blotting, Northern | 1 | 1989 | 203 | 0.000 |
Why?
|
| Genes | 1 | 1989 | 230 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1990 | 787 | 0.000 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1982 | 69 | 0.000 |
Why?
|